Preclinical Developments to be Highlighted: Delivery of siRNA to Bone Marrow and Proof of Concept Study Results

Fremont, California, December 20, 2007  –  Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates, announced today that it is scheduled to present at the JPMorgan 26th Annual Healthcare Conference on Wednesday, January 9, 2007. Daniel Zurr, Chief Executive Officer, and Gavin Samuels, M.D., Senior Vice President of Business Development, will participate in the presentation.
During the presentation, Quark plans to highlight recent preclinical developments, including the successful delivery of siRNA to bone marrow and preliminary results from recent proof of concept studies with siRNA, targeting different genes across several indications, including spinal cord injury and glaucomatous neuroprotection.

Event: JPMorgan 26th Annual Healthcare Conference
Date: Wednesday, January 9, 2008
Time: 4:00 p.m. PT
Place: Westin St. Francis Hotel, San Francisco, CA

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development and includes:

  • A proprietary gene discovery platform (BiFAR™) and algorithm for optimizing siRNA design
  • Novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the crowded siRNA intellectual property arena for its future product pipeline
  • The ability to deliver siRNA locally and systemically to organs including eye, ear, kidney, lung, spinal cord and bone marrow

Quark has a robust product portfolio including two clinical, one pre-IND and six preclinical candidates in development. Its lead product candidates are RTP801i-14, an siRNA molecule in phase I/IIa clinical trial for the treatment of wet age-related macular degeneration that is licensed to Pfizer on an exclusive worldwide basis. AKIi-5 is a Phase I, siRNA molecule, delivered systemically, for the prevention of acute kidney injury / acute renal failure following major cardiac surgery, and AHLi-11, a pre-IND siRNA molecule for the prevention of chemotherapy and noise-induced hearing loss.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available atwww.quarkpharma.com